Key features and details
- APC Mouse monoclonal [BNI3] to CTLA4
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: APC. Ex: 645nm, Em: 660nm
- Isotype: IgG2a
Product nameAPC Anti-CTLA4 antibody [BNI3]
See all CTLA4 primary antibodies
DescriptionAPC Mouse monoclonal [BNI3] to CTLA4
ConjugationAPC. Ex: 645nm, Em: 660nm
Tested applicationsSuitable for: Flow Cytmore details
Species reactivityReacts with: Human
Predicted to work with: Baboon, Cynomolgus monkey, Rhesus monkey
The details of the immunogen for this antibody are not available.
- Human peripheral blood lymphocytes.
This is a neutralizing antibody.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C. Store In the Dark.
Storage bufferpH: 7.20
Preservative: 0.09% Sodium azide
Constituents: 0.12% Monobasic dihydrogen sodium phosphate, 0.1% Gelatin, 0.87% Sodium chloride
Concentration information loading...
Purification notesPurified from tissue culture supernatant and conjugated under optimal conditions, with unreacted dye removed from the preparation.
Light chain typekappa
Our Abpromise guarantee covers the use of ab210253 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use 5µl for 105-8 cells.
in 100 μl volume.
FunctionInhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
Tissue specificityWidely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation.
Involvement in diseaseGenetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE) [MIM:152700]. SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system.
Note=Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism.
Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12) [MIM:601388]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
Genetic variation in CTLA4 is the cause of susceptibility to celiac disease type 3 (CELIAC3) [MIM:609755]. It is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins. In its classic form, celiac disease is characterized in children by malabsorption and failure to thrive.
Sequence similaritiesContains 1 Ig-like V-type (immunoglobulin-like) domain.
modificationsN-glycosylation is important for dimerization.
Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface.
Cellular localizationCell membrane. Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation and.
- Information by UniProt
- ALPS5 antibody
- CD 152 antibody
- CD antibody
ab210253 has not yet been referenced specifically in any publications.